Norma Carmen
Gutiérrez Gutiérrez
Profesora Asociada CC. Salud
![Foto de Norma Carmen](/img/nophoto.png)
![Foto de Hospital Universitario de Salamanca](/img/noimage_org.png)
Hospital Universitario de Salamanca
Salamanca, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario de Salamanca (195)
2024
-
A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma
Blood Advances, Vol. 8, Núm. 13, pp. 3478-3487
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology
-
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Haematologica
-
Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease
British Journal of Haematology, Vol. 205, Núm. 1, pp. 109-121
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
-
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 14, pp. 1612-1618
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
-
Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
Journal of Clinical Medicine, Vol. 13, Núm. 1
2023
-
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
British Journal of Haematology, Vol. 200, Núm. 3, pp. 306-314
-
Multiple myeloma with t(11;14): impact of novel agents on outcome
Blood Cancer Journal, Vol. 13, Núm. 1
-
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Cancers, Vol. 15, Núm. 5
2022
-
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710
-
Genomics of Plasma Cell Leukemia
Cancers, Vol. 14, Núm. 6
-
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma
Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
Experimental Hematology and Oncology, Vol. 11, Núm. 1
-
TCL-318 Evaluation of the Antitumor Activity of Amiloride in Peripheral T-Cell Lymphomas Using In-Vitro Models
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S399
-
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
British Journal of Haematology, Vol. 199, Núm. 3, pp. 344-354